MoonLake Immunotherapeutics (MLTX) said Wednesday that it has screened patients for for three new clinical trials targeting three new indications to assess sonelokimab, an investigational Nanobody aimed at treating inflammatory diseases.
The clinical program for sonelokimab now includes patients with adolescent hidradenitis suppurativa, or HS, palmoplantar pustulosis, or PPP, and axial spondyloarthritis, or axSpA, along with adult patients suffering from HS and active psoriatic arthritis, or PsA.
The new trials include the phase 3 VELA-TEEN trial in adolescent HS, which will evaluate safety and tolerability over 24 weeks in 30 to 40 adolescents; the phase 2 LEDA trial in PPP, assessing the efficacy of a 120mg subcutaneous dose in around 30 patients; and the phase 2 S-OLARIS trial in axSpA, using Positron Emission Tomography and Magnetic Resonance Imaging, or PET/MRI imaging to measure inflammation reduction in 25 patients, the biotechnology company said.
Shares of MoonLake were down 0.4% in recent Wednesday trading.
Price: 50.00, Change: -0.22, Percent Change: -0.43
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。